Market closedNon-fractional

Enanta/ENTA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Enanta

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Ticker

ENTA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Watertown, United States

Employees

145

Enanta Metrics

BasicAdvanced
$284M
Market cap
-
P/E ratio
-$6.25
EPS
0.54
Beta
-
Dividend rate
$284M
0.54
6.428
6.228
115.951
138.377
-12.14%
-22.87%
-60.50%
3.875
1.72
1.72
-2.493
-10.22%
4.22%
-8.18%
19.25%

What the Analysts think about Enanta

Analyst Ratings

Majority rating from 8 analysts.
Buy

Enanta Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-182.94% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$17M
-5.56%
Net income
-$31M
-6.89%
Profit margin
-182.94%
-1.41%

Enanta Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 10.31%
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$1.86
-$1.33
-$1.58
-$1.47
-
Expected
-$2.34
-$2.15
-$1.19
-$1.33
-$1.44
Surprise
-20.43%
-38.04%
32.33%
10.31%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Enanta stock?

Enanta (ENTA) has a market cap of $284M as of July 06, 2024.

What is the P/E ratio for Enanta stock?

The price to earnings (P/E) ratio for Enanta (ENTA) stock is 0 as of July 06, 2024.

Does Enanta stock pay dividends?

No, Enanta (ENTA) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Enanta dividend payment date?

Enanta (ENTA) stock does not pay dividends to its shareholders.

What is the beta indicator for Enanta?

Enanta (ENTA) has a beta rating of 0.54. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Enanta stock

Buy or sell Enanta stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing